Bone Regeneration Using PRF After Cyst Enucleation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Autologous Platelet-Rich Fibrin (PRF), Conventional Surgical Management.
- Who it may be relevant to
- Registry conditions: Odontogenic Cyst, Jaw Cysts, Osseous Defect After Cyst Enucleation. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Yemen
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Efficacy of Platelet-Rich Fibrin in Osseous Regeneration After Cystic Enucleation
Overview
This randomized controlled clinical trial aims to evaluate the clinical efficacy of autologous platelet-rich fibrin (PRF) in promoting osseous regeneration following cystic enucleation in the jaws. The study will assess bone healing outcomes and compare PRF application with conventional management methods.
Detailed description
This study is designed as a randomized controlled clinical trial to evaluate the effectiveness of autologous platelet-rich fibrin (PRF) in enhancing bone regeneration after cystic enucleation in the jaws.
PRF is an autologous biomaterial rich in growth factors that may enhance bone healing and tissue regeneration. Participants undergoing cystic enucleation will be randomly assigned to either a PRF-treated group or a control group receiving conventional treatment without PRF.
Clinical and radiographic assessments will be performed to evaluate bone regeneration, healing rate, and postoperative outcomes. If PRF demonstrates significant improvement in osseous regeneration, it may represent a minimally invasive and cost-effective alternative to traditional bone grafting procedures.
Ethical approval will be obtained from the Ethical Committee of the Faculty of Medicine and Health Sciences, Sana'a University, Yemen.
Interventions
- Biological Autologous Platelet-Rich Fibrin (PRF)
Autologous platelet-rich fibrin (PRF) prepared from the participant's own venous blood will be placed into the osseous defect immediately after cystic enucleation. PRF will be prepared using standard centrifugation protocols and applied to promote bone regeneration. - Procedure Conventional Surgical Management
Conventional cystic enucleation will be performed without the use of platelet-rich fibrin (PRF). The osseous defect will be managed according to standard surgical protocol and allowed to heal naturally.
Primary outcome measures
- Radiographic bone regeneration in cystic defects following enucleation [Time frame: 6 months after surgery]
Eligibility criteria
Inclusion criteria
- Patients diagnosed with odontogenic cysts requiring surgical enucleation.
- Presence of a postoperative osseous defect in the jaws after cyst enucleation.
- Age ≥ 18 years.
- Systemically healthy patients (ASA I or II).
- Patients willing to participate and sign informed consent.
Exclusion criteria
- Patients with systemic diseases affecting bone healing (e.g., uncontrolled diabetes, osteoporosis).
- Patients receiving bisphosphonates or long-term corticosteroid therapy.
- Smokers (>10 cigarettes/day).
- Pregnant or lactating women.
- Patients with acute infection at the surgical site.
- Patients unwilling to participate or unable to attend follow-up visits.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Yemen · 1 center
- Faculty of Medicine and Health Sciences - Sana'a University — Sanaa
Identifiers
NCT: NCT07424716 · OMFS:01/06/2025